MX2023001588A - Conjugados biciclo específicos para nectina-4 y usos de estos. - Google Patents
Conjugados biciclo específicos para nectina-4 y usos de estos.Info
- Publication number
- MX2023001588A MX2023001588A MX2023001588A MX2023001588A MX2023001588A MX 2023001588 A MX2023001588 A MX 2023001588A MX 2023001588 A MX2023001588 A MX 2023001588A MX 2023001588 A MX2023001588 A MX 2023001588A MX 2023001588 A MX2023001588 A MX 2023001588A
- Authority
- MX
- Mexico
- Prior art keywords
- nectin
- bicycle
- conjugates specific
- bicycle conjugates
- specific
- Prior art date
Links
- 102100035486 Nectin-4 Human genes 0.000 title abstract 2
- 101710043865 Nectin-4 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940044680 immune agonist Drugs 0.000 abstract 1
- 239000012651 immune agonist Substances 0.000 abstract 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente invención hace referencia a un conjugado de toxina Biciclo o a un agonista inmunológico dirigido a tumores Biciclo específico para nectina-4, o sales farmacéuticamente aceptables de estos, o composiciones farmacéuticamente aceptables de estos, y usos de estos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063066434P | 2020-08-17 | 2020-08-17 | |
US202163134202P | 2021-01-06 | 2021-01-06 | |
US202163171654P | 2021-04-07 | 2021-04-07 | |
PCT/EP2021/072866 WO2022038158A1 (en) | 2020-08-17 | 2021-08-17 | Bicycle conjugates specific for nectin-4 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001588A true MX2023001588A (es) | 2023-05-03 |
Family
ID=77666485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001588A MX2023001588A (es) | 2020-08-17 | 2021-08-17 | Conjugados biciclo específicos para nectina-4 y usos de estos. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4196792A1 (es) |
JP (1) | JP2023538906A (es) |
KR (1) | KR20230074721A (es) |
CN (1) | CN116234931A (es) |
AU (1) | AU2021327130A1 (es) |
CA (1) | CA3186504A1 (es) |
IL (1) | IL300450A (es) |
MX (1) | MX2023001588A (es) |
WO (1) | WO2022038158A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
KR20230146528A (ko) * | 2021-01-11 | 2023-10-19 | 바이사이클티엑스 리미티드 | 암을 치료하기 위한 방법 |
CN116768978A (zh) * | 2022-03-11 | 2023-09-19 | 上海智肽生物科技有限公司 | Nectin-4靶向肽化合物及其药物偶联物 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1121519C (zh) | 1999-01-18 | 2003-09-17 | 特沃罗恩产品有限公司 | 含高线密度比两组线的织物的抗穿透材料 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AU2002253619B2 (en) | 2001-04-27 | 2007-05-17 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same active ingredients |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
CA2531069A1 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
PT1856135E (pt) | 2005-01-19 | 2010-02-26 | Rigel Pharmaceuticals Inc | Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
JP5132550B2 (ja) | 2005-05-12 | 2013-01-30 | アボット・ラボラトリーズ | アポトーシス促進剤 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
KR20140033237A (ko) | 2005-10-07 | 2014-03-17 | 엑셀리시스, 인코포레이티드 | 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법 |
BR122021011788B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
RS58113B1 (sr) | 2005-12-13 | 2019-02-28 | Incyte Holdings Corp | Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CL2007001165A1 (es) | 2006-04-26 | 2008-01-25 | Hoffmann La Roche | 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares. |
US7514444B2 (en) | 2006-09-22 | 2009-04-07 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
BR122020010759B1 (pt) | 2007-03-12 | 2021-06-29 | Ym Biosciences Australia Pty Ltd | Compostos de fenil amino pirimidina inibidores de proteína quinases, processo para a preparação do composto, composição farmacêutica, e, implante |
US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
PT2257624E (pt) | 2008-02-05 | 2012-05-29 | Medical Res Council | Métodos e composições |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
KR20110013421A (ko) | 2008-05-29 | 2011-02-09 | 생-고뱅 생트레 드 레체르체 에 데투드 유로삐엔 | 알루미늄 티타네이트 함유 다공질 구조물 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
SI2510010T1 (sl) | 2009-12-10 | 2016-02-29 | F. Hoffmann-La Roche Ag | Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba |
JP2013521765A (ja) | 2010-03-05 | 2013-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトcsf−1rに対する抗体及びその使用 |
CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
NZ626610A (en) | 2010-05-04 | 2015-11-27 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
EP2614082B1 (en) | 2010-09-09 | 2018-10-03 | Pfizer Inc | 4-1bb binding molecules |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CN104159921B (zh) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
AU2012374617B2 (en) | 2012-05-11 | 2015-09-17 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
MX2020010444A (es) | 2018-04-04 | 2021-01-08 | Bicycletx Ltd | Complejos de péptidos bicíclicos en heterotándem. |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
-
2021
- 2021-08-17 WO PCT/EP2021/072866 patent/WO2022038158A1/en active Application Filing
- 2021-08-17 KR KR1020237008781A patent/KR20230074721A/ko unknown
- 2021-08-17 CN CN202180063232.XA patent/CN116234931A/zh active Pending
- 2021-08-17 JP JP2023511946A patent/JP2023538906A/ja active Pending
- 2021-08-17 CA CA3186504A patent/CA3186504A1/en active Pending
- 2021-08-17 MX MX2023001588A patent/MX2023001588A/es unknown
- 2021-08-17 EP EP21766420.0A patent/EP4196792A1/en active Pending
- 2021-08-17 AU AU2021327130A patent/AU2021327130A1/en active Pending
- 2021-08-17 IL IL300450A patent/IL300450A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022038158A1 (en) | 2022-02-24 |
JP2023538906A (ja) | 2023-09-12 |
IL300450A (en) | 2023-04-01 |
AU2021327130A1 (en) | 2023-03-02 |
KR20230074721A (ko) | 2023-05-31 |
EP4196792A1 (en) | 2023-06-21 |
CN116234931A (zh) | 2023-06-06 |
CA3186504A1 (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001588A (es) | Conjugados biciclo específicos para nectina-4 y usos de estos. | |
EP4316524A3 (en) | Camptothecin derivatives | |
MX2022006001A (es) | Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos. | |
MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
WO2018098269A3 (en) | Peptide-containing linkers for antibody-drug conjugates | |
ZA201805336B (en) | Amanitin conjugates | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
NZ720743A (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
MY196189A (en) | Cross-Linked Pyrrolobenzodiazepine Dimer (Pbd) Derivative and Its Conjugates | |
PH12016500904B1 (en) | Anti-her2 antibody-drug conjugate | |
MX2020012997A (es) | Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso. | |
WO2017089890A8 (en) | Conjugates comprising self-immolative groups and methods related thereto | |
MX2019007604A (es) | Novedoso conjugado de amanitina. | |
NZ754810A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
MX2021004069A (es) | Enlazadores de conjugacion que contienen el grupo 2,3-diaminosuccinilo. | |
MY170251A (en) | Antibody-drug conjugate | |
MX2022002592A (es) | Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo. | |
HK1155070A1 (en) | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 - | |
WO2016127081A8 (en) | Antibody drug conjugates | |
ZA202001747B (en) | Psma-targeting amanitin conjugates | |
MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
MX2022008437A (es) | Conjugados fármaco-anticuerpo específicos de sitio con enlazadores que contienen péptidos. | |
EP4054648A4 (en) | ANTIBODY-DRUG CONJUGATES TARGETING CLAUDINE 18.2 |